Location: Bordeaux, France
Thomas Lingelbach, Chief Executive Officer of Valneva, will participate in 1on1 and small group investor meetings, as well as a roundtable discussion on “Prevention and early detection – Post-COVID perspectives for diagnostics, vaccines & therapeutics,” alongside Emma Walmsley, CEO of GSK; Thierry Bernard, CEO of Qiagen and Chair of AdvaMedDx; Mark Miller, EVP and Chief Medical Officer of bioMerieux; and Dr Jean-Paul Stahl, Head of the Department of Infectious Diseases; University Hospital, Grenoble (France) and former President of the French Infectious Diseases Society.